SCHEMBL5869782

SCHEMBL5869782

CC(C)C[C@H](N[C@@H](Cc1ccc(C(=O)OC(C)(C)C)cc1)C(=O)O)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 2/20 0.48
▸ MAPK1 P28482 1/20 0.44
▸ SLC7A5 Q01650 1/20 0.43
▸ MME P08473 3/20 0.42
▸ ACE P12821 2/20 0.42
▸ GRN P28799 1/20 0.42
▸ SORT1 Q99523 1/20 0.42
▸ CPA1 P15085 1/20 0.42
▸ ACE2 Q9BYF1 1/20 0.42
▸ ITGB3 P05106 1/20 0.42
▸ ITGA2B P08514 1/20 0.42
▸ REN P00797 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ PPARG P37231 3/20 0.41
▸ PPARA Q07869 3/20 0.41
▸ PPARD Q03181 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5869787 1.00 FOLH1 (0.48) FOLH1MAPK1SLC7A5MMEACE
SCHEMBL8258366 0.82 FOLH1 (0.50) FOLH1MMEACEGRNSORT1
SCHEMBL5869302 0.82 FOLH1 (0.50) FOLH1MMEACEGRNSORT1
SCHEMBL15876045 0.82 ITGB3 (0.47) SLC7A5MMEACEACE2ITGB3
SCHEMBL9442952 0.81 REN (0.57) MAPK1MMEACERENPOLB
SCHEMBL9442931 0.81 REN (0.57) MAPK1MMEACERENPOLB
SCHEMBL5869365 0.81 FOLH1 (0.49) FOLH1MMEACEGRNSORT1
SCHEMBL7326560 0.81 REN (0.57) MAPK1MMEACERENPOLB
SCHEMBL8249675 0.81 FOLH1 (0.49) FOLH1MMEACEGRNSORT1
SCHEMBL5374891 0.81 ACE (0.61) ACEITGB3ITGA2BPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7045532-B2 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-16 — — US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 — — US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 — — US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof ACE, ACE2, AGTR2 FOLH1 229/4885MAPK1 1850/4885SLC7A5 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback